---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-013461"
form_type: "8-K"
ticker: "BVS"
cik: "0001665988"
company_name: "Bioventus Inc."
filed_at: "2022-05-10T23:59:59+00:00"
generated_at: "2026-06-25T21:45:41.144271+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Bioventus Q1 net loss $14.8M vs prior-year income; reaffirms FY22 guidance

## Summary
- Net sales $117.3M (+43.4% YoY as reported, +8.6% organic); Pain Treatments +25.3%, Restorative Therapies +57.5%, Surgical Solutions +67.6%.
- Net loss of ($14.8M) compared to net income of $24.5M in Q1 2021; Adjusted EBITDA $7.1M vs $11.1M.
- Reaffirms FY2022 guidance: net sales $545M-$565M, Adjusted EBITDA $94M-$107M.
- Cash $27.4M; debt $368.3M as of April 2, 2022.

## SEC filing metadata
- accession: 0001628280-22-013461
- form_type: 8-K
- ticker: BVS
- cik: 0001665988
- company_name: Bioventus Inc.
- filed_at: 2022-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1665988/000162828022013461/0001628280-22-013461-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1665988/000162828022013461/bvs-20220510.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-013461
- JSON: https://secwatch.observer/filing/0001628280-22-013461.json
- Plain text: https://secwatch.observer/filing/0001628280-22-013461.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.